From Name

From Email

To Name

To Email

Message

US FDA approves GlaxoSmithKline’s blood cancer drug

from CNBC

US FDA approves GlaxoSmithKline’s blood cancer drug CNBC The U.S. Food and Drug Administration on Aug. 5 approved GlaxoSmithKline’s experimental treatment for a common form of blood cancer. GSK’s belantamab mafodotin, or BLENREP, was approved for treating adults with relapsed and refractory multiple myeloma who no longer respond to treatment with an immunomodulatory agent, the drugmaker said in a statement. READ MORE

more